Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis
View/ Open
Becker_RationaleDesignAndGovernanceOfProspectiveRandomizedEvaluationOfCelecoxib_AmHeartJ_2009.pdf (221.3Kb)
Access Status
Full text of the requested work is not available in DASH at this time ("restricted access"). For more information on restricted deposits, see our FAQ.Author
Becker, Matthew C.
Wang, Thomas H.
Wisniewski, Lisa
Wolski, Kathy
Lüscher, Thomas F.
Borer, Jeffrey S.
Mascette, Alice M.
Husni, M. Elaine
Graham, David Y.
Yeomans, Neville D.
Krum, Henry
Ruschitzka, Frank
Lincoff, A. Michael
Nissen, Steven E.
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1016/j.ahj.2008.12.014Metadata
Show full item recordCitation
Becker, Matthew C., Thomas H. Wang, Lisa Wisniewski, Kathy Wolski, Peter Libby, Thomas F. Lüscher, Jeffrey S. Borer, et al. 2009. “Rationale, Design, and Governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen Or Naproxen (PRECISION), a Cardiovascular End Point Trial of Nonsteroidal Antiinflammatory Agents in Patients with Arthritis.” American Heart Journal 157 (4) (April): 606–612. doi:10.1016/j.ahj.2008.12.014.Abstract
BackgroundPain management in patients with osteoarthritis or rheumatoid arthritis often requires long-term use of nonsteroidal antiinflammatory drugs (NSAIDs). However, the relative cardiovascular safety of these therapies remains uncertain.
Methods
The Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION) trial will evaluate the cardiovascular safety of celecoxib, ibuprofen, and naproxen. Approximately 20,000 patients with symptomatic osteoarthritis or rheumatoid arthritis at high risk for, or with, established cardiovascular disease will be randomized in this double-blind, triple dummy, multinational, multicenter study. The primary end point is the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The trial will continue until 762 primary events occur with at least 18 months follow-up. Noninferiority of any of the regimens will require a 97.5% upper CI of the hazard ratio (HR) ≤1.33 and point estimate ≤1.12 for both intent-to-treat (ITT) and modified ITT populations.
Conclusion
PRECISION, the first study of patients with high cardiovascular risk chronically treated with a cyclooxygenase-2 selective inhibitor or nonselective NSAID, will define the relative cardiovascular safety profile of celecoxib, ibuprofen, and naproxen and provide data to help guide NSAID use for pain management for this population. (Am Heart J 2009;157:606-12.)
Other Sources
http://www.researchgate.net/publication/24244523_Rationale_design_and_governance_of_Prospective_Randomized_Evaluation_of_Celecoxib_Integrated_Safety_versus_Ibuprofen_Or_Naproxen_(PRECISION)_a_cardiovascular_end_point_trial_of_nonsteroidal_antiinflammatory_agents_in_patients_with_arthritis/links/02bfe50ca54d2e1d41000000http://www.ncbi.nlm.nih.gov/pubmed/19332185
Citable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:35140981
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)